Argus
•
Nov 04, 2026
Bristol-Myers Squibb Company: Raising earnings estimate for 2027
Summary
Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. BMY shares are a component of the S&P 500.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: CVS Health Corp
Nov 10, 2026
•
CVS
Market Digest: CSX, CVS, HIG, VIAV, MCHP, OGE, DLR, AXON
Nov 10, 2026
•
VIAV, CVS, HIG, AXON, CSX, MCHP, DLR, OGE
Daily Spotlight: Is Gridlock Good?
Nov 09, 2026
•
ABBV
Analyst Report: AbbVie Inc
Nov 06, 2026
•
ABBV
Market Digest: FIS, MCD, SPGI, NUE, SMCI, APO, ABBV, PPC, APP
Nov 06, 2026
•
APO, APP, FIS, PPC, SMCI, SPGI, ABBV, NUE, MCD
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
